Cantor Fitzgerald restated their buy rating on shares of Gilead Sciences (NASDAQ:GILD) in a research report released on Thursday morning, AnalystRatings.com reports. The brokerage currently has a $87.00 price objective on the biopharmaceutical company’s stock.
“. We reiterate our Overweight rating and $87 Price Target. We do not think today’s announcement that GILD’s STELLAR3 study was unsuccessful will be met with much surprise after the previous STELLAR4 failure: no changes to our estimates. The fibrosis improvement was least for the high dose and greatest for the placebo with a p-value at the higher dose of 0.42 and at lower dose it was 0.93. After both STELLAR Ph3 readouts we are focused on how Gilead will advance its strategy in NASH; we think M&A could be a strategy.”,” Cantor Fitzgerald’s analyst wrote.
Several other research firms also recently weighed in on GILD. Raymond James cut their target price on Gilead Sciences from $90.00 to $85.00 and set a strong-buy rating on the stock in a research report on Tuesday, February 12th. BMO Capital Markets initiated coverage on Gilead Sciences in a research report on Thursday, March 14th. They set an outperform rating and a $78.00 target price on the stock. Zacks Investment Research raised Gilead Sciences from a hold rating to a buy rating and set a $69.00 target price on the stock in a research report on Tuesday, April 23rd. Wells Fargo & Co cut their target price on Gilead Sciences from $95.00 to $89.00 and set an outperform rating on the stock in a research report on Tuesday, February 5th. Finally, Piper Jaffray Companies set a $75.00 target price on Gilead Sciences and gave the company a hold rating in a research report on Thursday, March 7th. Two equities research analysts have rated the stock with a sell rating, seven have given a hold rating and fourteen have given a buy rating to the stock. Gilead Sciences has a consensus rating of Buy and a consensus target price of $80.94.
Shares of GILD opened at $65.15 on Thursday. The company has a market cap of $83.06 billion, a PE ratio of 10.59, a PEG ratio of 1.02 and a beta of 1.16. Gilead Sciences has a 1 year low of $60.32 and a 1 year high of $79.61. The company has a debt-to-equity ratio of 1.19, a quick ratio of 3.30 and a current ratio of 3.38.
Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings data on Monday, February 4th. The biopharmaceutical company reported $1.44 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.70 by ($0.26). The firm had revenue of $5.80 billion for the quarter, compared to analysts’ expectations of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm’s revenue was down 2.6% on a year-over-year basis. During the same period last year, the company earned $1.78 earnings per share. As a group, equities analysts forecast that Gilead Sciences will post 6.3 EPS for the current fiscal year.
In other news, Director John Francis Cogan sold 2,700 shares of the stock in a transaction on Wednesday, March 20th. The stock was sold at an average price of $65.07, for a total transaction of $175,689.00. Following the transaction, the director now owns 57,560 shares of the company’s stock, valued at approximately $3,745,429.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Richard James Whitley sold 9,534 shares of the stock in a transaction on Monday, April 1st. The stock was sold at an average price of $65.48, for a total value of $624,286.32. Following the transaction, the director now directly owns 34,669 shares in the company, valued at approximately $2,270,126.12. The disclosure for this sale can be found here. Insiders sold a total of 44,802 shares of company stock worth $2,956,422 in the last ninety days. 0.20% of the stock is currently owned by corporate insiders.
Several institutional investors and hedge funds have recently bought and sold shares of the company. Gradient Investments LLC raised its stake in Gilead Sciences by 16.1% in the fourth quarter. Gradient Investments LLC now owns 1,076 shares of the biopharmaceutical company’s stock valued at $67,000 after buying an additional 149 shares during the last quarter. Vectors Research Management LLC raised its stake in Gilead Sciences by 6.3% in the fourth quarter. Vectors Research Management LLC now owns 2,651 shares of the biopharmaceutical company’s stock valued at $166,000 after buying an additional 157 shares during the last quarter. Waldron Private Wealth LLC raised its stake in Gilead Sciences by 3.8% in the third quarter. Waldron Private Wealth LLC now owns 4,372 shares of the biopharmaceutical company’s stock valued at $337,000 after buying an additional 162 shares during the last quarter. Creative Financial Designs Inc. ADV raised its stake in Gilead Sciences by 55.9% in the first quarter. Creative Financial Designs Inc. ADV now owns 460 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 165 shares during the last quarter. Finally, Cornerstone Advisors Inc. raised its stake in Gilead Sciences by 6.1% in the third quarter. Cornerstone Advisors Inc. now owns 3,120 shares of the biopharmaceutical company’s stock valued at $241,000 after buying an additional 178 shares during the last quarter. 80.21% of the stock is currently owned by institutional investors and hedge funds.
Gilead Sciences Company Profile
Gilead Sciences, Inc is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases.
See Also: What Are Cryptocurrencies?
Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.